Cargando…

Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer

Two miniaturized electrochemical devices were designed for the simultaneous bioanalysis of MMR (MLH1, MSH2, MSH6, PMS2), and of KRAS in whole blood, urine, saliva, and tumoral tissues. The devices comprised besides the electronic part of the potentiostat a combined 3D stochastic microsensor (combine...

Descripción completa

Detalles Bibliográficos
Autores principales: Stefan-van Staden, Raluca-Ioana, Bratei, Alexandru Adrian, Ilie-Mihai, Ruxandra-Maria, Gheorghe, Damaris-Cristina, Tuchiu, Bianca Maria, Gurzu, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415748/
https://www.ncbi.nlm.nih.gov/pubmed/37577090
http://dx.doi.org/10.1039/d3ra04260j
_version_ 1785087612663365632
author Stefan-van Staden, Raluca-Ioana
Bratei, Alexandru Adrian
Ilie-Mihai, Ruxandra-Maria
Gheorghe, Damaris-Cristina
Tuchiu, Bianca Maria
Gurzu, Simona
author_facet Stefan-van Staden, Raluca-Ioana
Bratei, Alexandru Adrian
Ilie-Mihai, Ruxandra-Maria
Gheorghe, Damaris-Cristina
Tuchiu, Bianca Maria
Gurzu, Simona
author_sort Stefan-van Staden, Raluca-Ioana
collection PubMed
description Two miniaturized electrochemical devices were designed for the simultaneous bioanalysis of MMR (MLH1, MSH2, MSH6, PMS2), and of KRAS in whole blood, urine, saliva, and tumoral tissues. The devices comprised besides the electronic part of the potentiostat a combined 3D stochastic microsensor (combined microplatform) with the sensing part based on the modification of graphene decorated with nitrogen, sulfur and boron (NSB-EGR) modified with two types of frutafit: FTEX and FHD. For the assay of MSH2, MSH6, KRAS, and PMS2 higher sensitivities were recorded when the microdevice based on FHD was used, while for the assay of MLH1 the best sensitivity was achieved by using the microdevice based on FTEX. While the limits of quantification for MLH1, MSH2, and PMS2 were not influenced by the modifier, the microdevice based on FHD provided the lowest limit of quantification for KRAS, the microdevice based on FTEX provided the lowest limit of quantification for MSH6. The validation tests performed proved that recoveries of MLH1, MSH2, MSH6, PMS2, and of KRAS in whole blood, urine, saliva, and tumoral tissues higher than 98.50% with RSD (%) values lower than 0.10% were recorded.
format Online
Article
Text
id pubmed-10415748
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-104157482023-08-12 Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer Stefan-van Staden, Raluca-Ioana Bratei, Alexandru Adrian Ilie-Mihai, Ruxandra-Maria Gheorghe, Damaris-Cristina Tuchiu, Bianca Maria Gurzu, Simona RSC Adv Chemistry Two miniaturized electrochemical devices were designed for the simultaneous bioanalysis of MMR (MLH1, MSH2, MSH6, PMS2), and of KRAS in whole blood, urine, saliva, and tumoral tissues. The devices comprised besides the electronic part of the potentiostat a combined 3D stochastic microsensor (combined microplatform) with the sensing part based on the modification of graphene decorated with nitrogen, sulfur and boron (NSB-EGR) modified with two types of frutafit: FTEX and FHD. For the assay of MSH2, MSH6, KRAS, and PMS2 higher sensitivities were recorded when the microdevice based on FHD was used, while for the assay of MLH1 the best sensitivity was achieved by using the microdevice based on FTEX. While the limits of quantification for MLH1, MSH2, and PMS2 were not influenced by the modifier, the microdevice based on FHD provided the lowest limit of quantification for KRAS, the microdevice based on FTEX provided the lowest limit of quantification for MSH6. The validation tests performed proved that recoveries of MLH1, MSH2, MSH6, PMS2, and of KRAS in whole blood, urine, saliva, and tumoral tissues higher than 98.50% with RSD (%) values lower than 0.10% were recorded. The Royal Society of Chemistry 2023-08-11 /pmc/articles/PMC10415748/ /pubmed/37577090 http://dx.doi.org/10.1039/d3ra04260j Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Stefan-van Staden, Raluca-Ioana
Bratei, Alexandru Adrian
Ilie-Mihai, Ruxandra-Maria
Gheorghe, Damaris-Cristina
Tuchiu, Bianca Maria
Gurzu, Simona
Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer
title Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer
title_full Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer
title_fullStr Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer
title_full_unstemmed Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer
title_short Bioanalysis of MMR and KRAS – a key factor in diagnosis of colorectal cancer
title_sort bioanalysis of mmr and kras – a key factor in diagnosis of colorectal cancer
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10415748/
https://www.ncbi.nlm.nih.gov/pubmed/37577090
http://dx.doi.org/10.1039/d3ra04260j
work_keys_str_mv AT stefanvanstadenralucaioana bioanalysisofmmrandkrasakeyfactorindiagnosisofcolorectalcancer
AT brateialexandruadrian bioanalysisofmmrandkrasakeyfactorindiagnosisofcolorectalcancer
AT iliemihairuxandramaria bioanalysisofmmrandkrasakeyfactorindiagnosisofcolorectalcancer
AT gheorghedamariscristina bioanalysisofmmrandkrasakeyfactorindiagnosisofcolorectalcancer
AT tuchiubiancamaria bioanalysisofmmrandkrasakeyfactorindiagnosisofcolorectalcancer
AT gurzusimona bioanalysisofmmrandkrasakeyfactorindiagnosisofcolorectalcancer